• Users Online: 532
  • Print this page
  • Email this page
ORIGINAL ARTICLE
Year : 2017  |  Volume : 8  |  Issue : 4  |  Page : 246-249

A real-world study to assess the effectiveness of itolizumab in patients with chronic plaque psoriasis


1 Department of Dermatology, Dr Anchala's Skin Clinic, Hyderabad, Telangana, India
2 Department of Dermatology, Vibrance Skin Clinic, New Delhi, India
3 Department of Dermatology, Leelavati Hospital, Mumbai, Maharashtra, India
4 Department of Dermatology, ESI Hospital, Okla, New Delhi, India
5 Department of Dermatology, Mallige Hospital, Bengaluru, Karnataka, India
6 Department of Dermatology, ESI Okhla, New Delhi, India

Correspondence Address:
Anchala Parthasaradhi
Dr Anchala Skin Institute and Research Center, House No B-20, Journalist Colony, Jubilee Hills, Hyderabad, Telangana - 500 033
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/idoj.IDOJ_330_16

Rights and Permissions

Background: While clinical trial data on the efficacy of itolizumab in the management of psoriasis is relatively well documented, data on the effectiveness of this humanized IgG1 monoclonal antibody in real-world settings is sparse. Aims: The current study assessed the effectiveness of itolizumab in real-world settings. Materials and Methods: This study assessed psoriasis area severity index (PASI), dermatology quality of life index (DLQI), safety, and tolerability data from a registry of itolizumab maintained by Syngene International, Bangalore. Registry data of 155 patients who were prescribed itolizumab at a dose of 1.6 mg/kg every 2 weeks for the first 12 weeks followed by 1.6 mg/kg every 4 weeks for up to 24 weeks for chronic plaque psoriasis. Results: In the study, 35.48% completed itolizumab for 12 weeks and 76.59% of these patients achieved PASI 75. Furthermore, 24.51% patients completed the full Itolizumab regimen for 24 weeks, of whom 92.01% patients achieved PASI 75. The mean percent change in DLQI scores at weeks 12 and 24 were 60.19 and 82.72, respectively. Adverse events and infusion reactions noted in the study were generally of mild to moderate severity. Conclusion: Itolizumab is a safe and effective option in treatment-compliant patients with chronic plaque psoriasis. Effects of putative compliance-modulators such as cost, route of administration, and delayed onset of action warrant further investigation.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed413    
    Printed23    
    Emailed0    
    PDF Downloaded146    
    Comments [Add]    

Recommend this journal